Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
复制标题
DOI：
10.3904/kjim.2015.158
复制
发表时间：
2018-01
期刊：
影响因子：
--
通讯作者：
Cho EK
中科院分区：
文献类型：
--
作者：
Baek MY;Ahn HK;Park KR;Park HS;Kang SM;Park I;Kim YS;Hong J;Sym SJ;Park J;Lee JH;Shin DB;Cho EK
我们研究了转移性非小细胞肺癌（NSCLC）患者发生脑转移（BM）所需的时间，以及诊断后的总中位生存期，考虑到表皮生长因子受体（EGFR）突变状态。我们回顾性调查了2010年1月至2013年8月诊断为晚期NSCLC的259例患者的病历，这些患者接受了EGFR突变检测。根据EGFR突变状态评估并比较从诊断晚期非小细胞肺癌到出现BM的时间以及出现BM后的总中位生存期（BM-OS）。67例患者（25.9%）发生BM。EGFR突变型（MT）患者的同步BM发生率（n = 20，27.4%）高于EGFR野生型（WT）患者（n = 27，14.5%，p < 0.009）。EGFR MT患者的中位BM-OS显著长于EGFR WT患者（25. 7个月vs. 3. 8个月，p <0. 001），同步BM患者也观察到类似趋势（EGFR MT为25. 7个月vs. EGFR WT为6. 8个月，p <0. 001）。然而，在异时性BM发生的患者中，EGFR MT（14.6个月）和EGFR WT（2.5个月）患者之间的BM-OS差异未达到统计学显著性（p = 0.230）。EGFR MT的NSCLC患者中同步BM比EGFR WT患者更常见。然而，EGFR突变与中位BM-OS显著延长相关，尤其是当脑是第一个转移部位时。
We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status. We retrospectively investigated the medical records of 259 patients diagnosed with advanced NSCLC from January 2010 to August 2013, who were tested for EGFR mutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development (BM-OS) were evaluated and compared by EGFR mutational status. Sixty-seven patients (25.9%) developed BM. Synchronous BM occurred more often in patients with EGFR mutation type (MT) (n = 20, 27.4%) compared with EGFR wild type (WT) (n = 27, 14.5%, p < 0.009). The median BM-OS was significantly longer in patients with EGFR MT than in those with EGFR WT (25.7 months vs. 3.8 months, p < 0.001), and a similar trend was noticed for patients with synchronous BM (25.7 months for EGFR MT vs. 6.8 months for EGFR WT, p < 0.001). However, in patients with metachronous BM development, the difference in BM-OS between patients with EGFR MT (14.6 months) and EGFR WT (2.5 months) did not reach statistical significance (p = 0.230). Synchronous BM was more common in NSCLC patients with EGFR MT than in those with EGFR WT. However, EGFR mutations were associated with significantly longer median BM-OS, especially when the brain was the first metastatic site.
登录
查看更多内容
影响因子：
51.1
作者：
Zhou, Caicun;Wu, Yi-Long;You, Changxuan
通讯作者：
You, Changxuan
影响因子：
45.3
作者：
Sperduto, Paul W.;Kased, Norbert;Mehta, Minesh
通讯作者：
Mehta, Minesh
影响因子：
158.5
作者：
Mok, Tony S.;Wu, Yi-Long;Fukuoka, Masahiro
通讯作者：
Fukuoka, Masahiro
影响因子：
2.4
作者：
Stanic K;Zwitter M;Hitij NT;Kern I;Sadikov A;Cufer T
通讯作者：
Cufer T
表皮生长因子受体过表达参与促进乳腺癌脑转移
影响因子：
6.2
作者：
Nie, Fang;Yang, Jian;Teng, Gao-Jun
通讯作者：
Teng, Gao-Jun